Subscribe
shutterstock_742316485_chrisdorney
chrisdorney / Shutterstock.com
14 September 2020AmericasSarah Morgan

Gilead to buy Immunomedics for $21bn

Gilead Sciences is set to acquire biopharmaceutical company Immunomedics in a $21 billion deal, further strengthening its oncology expertise.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
J&J announces $6.5bn Momenta acquisition, days after Sanofi deal
20 August 2020   Johnson & Johnson is set to buy biotech Massachusetts-based Momenta Pharmaceuticals for $6.5 billion, in a move aimed at strengthening its portfolio of autoimmune disease treatments.
Americas
Merck & Co to buy $1bn stake in Seattle Genetics
16 September 2020   Merck & Co is set to make a $1 billion investment in biotech company Seattle Genetics, as the companies collaborate to develop and sell Seattle Genetics’ cancer therapy, ladiratuzumab vedotin.
Americas
BMS boosts cardio portfolio with $13bn buy
6 October 2020   Bristol Myers Squibb has announced it will acquire biotech firm MyoKardia for $13.1 billion, strengthening its portfolio of heart disease treatments.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
J&J announces $6.5bn Momenta acquisition, days after Sanofi deal
20 August 2020   Johnson & Johnson is set to buy biotech Massachusetts-based Momenta Pharmaceuticals for $6.5 billion, in a move aimed at strengthening its portfolio of autoimmune disease treatments.
Americas
Merck & Co to buy $1bn stake in Seattle Genetics
16 September 2020   Merck & Co is set to make a $1 billion investment in biotech company Seattle Genetics, as the companies collaborate to develop and sell Seattle Genetics’ cancer therapy, ladiratuzumab vedotin.
Americas
BMS boosts cardio portfolio with $13bn buy
6 October 2020   Bristol Myers Squibb has announced it will acquire biotech firm MyoKardia for $13.1 billion, strengthening its portfolio of heart disease treatments.

More on this story

Americas
J&J announces $6.5bn Momenta acquisition, days after Sanofi deal
20 August 2020   Johnson & Johnson is set to buy biotech Massachusetts-based Momenta Pharmaceuticals for $6.5 billion, in a move aimed at strengthening its portfolio of autoimmune disease treatments.
Americas
Merck & Co to buy $1bn stake in Seattle Genetics
16 September 2020   Merck & Co is set to make a $1 billion investment in biotech company Seattle Genetics, as the companies collaborate to develop and sell Seattle Genetics’ cancer therapy, ladiratuzumab vedotin.
Americas
BMS boosts cardio portfolio with $13bn buy
6 October 2020   Bristol Myers Squibb has announced it will acquire biotech firm MyoKardia for $13.1 billion, strengthening its portfolio of heart disease treatments.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?